Human Pegivirus infection and lymphoma risk and prognosis: A North American study

Angelo Fama, Jinhua Xiang, Brian K. Link, Cristine Allmer, Donna Klinzman, Andrew L Feldman, Grzegorz S Nowakowski, Mark Liebow, Melissa C. Larson, Matthew J. Maurer, Stephen Maxted Ansell, Anne J Novak, Yan Asmann, Susan L Slager, Timothy G. Call, Thomas Matthew Habermann, James R Cerhan, Jack T. Stapleton

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

We evaluated the association of Human Pegivirus (HPgV) viraemia with risk of developing lymphoma, overall and by major subtypes. Because this virus has also been associated with better prognosis in the setting of co-infection with human immunodeficiency virus, we further assessed the association of HPgV with prognosis. We used risk factor data and banked plasma samples from 2094 lymphoma cases newly diagnosed between 2002 and 2009 and 1572 frequency-matched controls. Plasma samples were tested for HPgV RNA by reverse transcription polymerase chain reaction (RT-PCR), and those with RNA concentrations <5000 genome equivalents/ml were confirmed using nested RT-PCR methods. To assess the role of HPgV in lymphoma prognosis, we used 2948 cases from a cohort study of newly diagnosed lymphoma patients (included all cases from the case-control study). There was a positive association of HPgV viraemia with risk of lymphoma overall (Odds ratio = 2·14; 95% confidence interval [CI] 1·63-2·80; P < 0·0001), and for all major subtypes except Hodgkin lymphoma and chronic lymphocytic leukaemia/small lymphocytic lymphoma, and this was not confounded by other lymphoma risk factors. In contrast, there was no association of HPgV viraemia with event-free survival (Hazard ratio [HR] = 1·00; 95% CI 0·85-1·18) or overall survival (HR = 0·97; 95% CI 0·79-1·20) for lymphoma overall, or any of the subtypes. These data support the hypothesis for a role of HPgV in the aetiology of multiple lymphoma subtypes.

Original languageEnglish (US)
JournalBritish Journal of Haematology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Lymphoma
Infection
Viremia
B-Cell Chronic Lymphocytic Leukemia
Confidence Intervals
Reverse Transcription
RNA
Polymerase Chain Reaction
Coinfection
Hodgkin Disease
Disease-Free Survival
Case-Control Studies
Cohort Studies
Odds Ratio
HIV
Genome
Viruses
Survival

Keywords

  • HPgV
  • Infection
  • Lymphoma
  • Prognosis
  • Risk

ASJC Scopus subject areas

  • Hematology

Cite this

Human Pegivirus infection and lymphoma risk and prognosis : A North American study. / Fama, Angelo; Xiang, Jinhua; Link, Brian K.; Allmer, Cristine; Klinzman, Donna; Feldman, Andrew L; Nowakowski, Grzegorz S; Liebow, Mark; Larson, Melissa C.; Maurer, Matthew J.; Ansell, Stephen Maxted; Novak, Anne J; Asmann, Yan; Slager, Susan L; Call, Timothy G.; Habermann, Thomas Matthew; Cerhan, James R; Stapleton, Jack T.

In: British Journal of Haematology, 01.01.2018.

Research output: Contribution to journalArticle

@article{7a626a66f3834855bda9f7b72997de4b,
title = "Human Pegivirus infection and lymphoma risk and prognosis: A North American study",
abstract = "We evaluated the association of Human Pegivirus (HPgV) viraemia with risk of developing lymphoma, overall and by major subtypes. Because this virus has also been associated with better prognosis in the setting of co-infection with human immunodeficiency virus, we further assessed the association of HPgV with prognosis. We used risk factor data and banked plasma samples from 2094 lymphoma cases newly diagnosed between 2002 and 2009 and 1572 frequency-matched controls. Plasma samples were tested for HPgV RNA by reverse transcription polymerase chain reaction (RT-PCR), and those with RNA concentrations <5000 genome equivalents/ml were confirmed using nested RT-PCR methods. To assess the role of HPgV in lymphoma prognosis, we used 2948 cases from a cohort study of newly diagnosed lymphoma patients (included all cases from the case-control study). There was a positive association of HPgV viraemia with risk of lymphoma overall (Odds ratio = 2·14; 95{\%} confidence interval [CI] 1·63-2·80; P < 0·0001), and for all major subtypes except Hodgkin lymphoma and chronic lymphocytic leukaemia/small lymphocytic lymphoma, and this was not confounded by other lymphoma risk factors. In contrast, there was no association of HPgV viraemia with event-free survival (Hazard ratio [HR] = 1·00; 95{\%} CI 0·85-1·18) or overall survival (HR = 0·97; 95{\%} CI 0·79-1·20) for lymphoma overall, or any of the subtypes. These data support the hypothesis for a role of HPgV in the aetiology of multiple lymphoma subtypes.",
keywords = "HPgV, Infection, Lymphoma, Prognosis, Risk",
author = "Angelo Fama and Jinhua Xiang and Link, {Brian K.} and Cristine Allmer and Donna Klinzman and Feldman, {Andrew L} and Nowakowski, {Grzegorz S} and Mark Liebow and Larson, {Melissa C.} and Maurer, {Matthew J.} and Ansell, {Stephen Maxted} and Novak, {Anne J} and Yan Asmann and Slager, {Susan L} and Call, {Timothy G.} and Habermann, {Thomas Matthew} and Cerhan, {James R} and Stapleton, {Jack T.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/bjh.15416",
language = "English (US)",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Human Pegivirus infection and lymphoma risk and prognosis

T2 - A North American study

AU - Fama, Angelo

AU - Xiang, Jinhua

AU - Link, Brian K.

AU - Allmer, Cristine

AU - Klinzman, Donna

AU - Feldman, Andrew L

AU - Nowakowski, Grzegorz S

AU - Liebow, Mark

AU - Larson, Melissa C.

AU - Maurer, Matthew J.

AU - Ansell, Stephen Maxted

AU - Novak, Anne J

AU - Asmann, Yan

AU - Slager, Susan L

AU - Call, Timothy G.

AU - Habermann, Thomas Matthew

AU - Cerhan, James R

AU - Stapleton, Jack T.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - We evaluated the association of Human Pegivirus (HPgV) viraemia with risk of developing lymphoma, overall and by major subtypes. Because this virus has also been associated with better prognosis in the setting of co-infection with human immunodeficiency virus, we further assessed the association of HPgV with prognosis. We used risk factor data and banked plasma samples from 2094 lymphoma cases newly diagnosed between 2002 and 2009 and 1572 frequency-matched controls. Plasma samples were tested for HPgV RNA by reverse transcription polymerase chain reaction (RT-PCR), and those with RNA concentrations <5000 genome equivalents/ml were confirmed using nested RT-PCR methods. To assess the role of HPgV in lymphoma prognosis, we used 2948 cases from a cohort study of newly diagnosed lymphoma patients (included all cases from the case-control study). There was a positive association of HPgV viraemia with risk of lymphoma overall (Odds ratio = 2·14; 95% confidence interval [CI] 1·63-2·80; P < 0·0001), and for all major subtypes except Hodgkin lymphoma and chronic lymphocytic leukaemia/small lymphocytic lymphoma, and this was not confounded by other lymphoma risk factors. In contrast, there was no association of HPgV viraemia with event-free survival (Hazard ratio [HR] = 1·00; 95% CI 0·85-1·18) or overall survival (HR = 0·97; 95% CI 0·79-1·20) for lymphoma overall, or any of the subtypes. These data support the hypothesis for a role of HPgV in the aetiology of multiple lymphoma subtypes.

AB - We evaluated the association of Human Pegivirus (HPgV) viraemia with risk of developing lymphoma, overall and by major subtypes. Because this virus has also been associated with better prognosis in the setting of co-infection with human immunodeficiency virus, we further assessed the association of HPgV with prognosis. We used risk factor data and banked plasma samples from 2094 lymphoma cases newly diagnosed between 2002 and 2009 and 1572 frequency-matched controls. Plasma samples were tested for HPgV RNA by reverse transcription polymerase chain reaction (RT-PCR), and those with RNA concentrations <5000 genome equivalents/ml were confirmed using nested RT-PCR methods. To assess the role of HPgV in lymphoma prognosis, we used 2948 cases from a cohort study of newly diagnosed lymphoma patients (included all cases from the case-control study). There was a positive association of HPgV viraemia with risk of lymphoma overall (Odds ratio = 2·14; 95% confidence interval [CI] 1·63-2·80; P < 0·0001), and for all major subtypes except Hodgkin lymphoma and chronic lymphocytic leukaemia/small lymphocytic lymphoma, and this was not confounded by other lymphoma risk factors. In contrast, there was no association of HPgV viraemia with event-free survival (Hazard ratio [HR] = 1·00; 95% CI 0·85-1·18) or overall survival (HR = 0·97; 95% CI 0·79-1·20) for lymphoma overall, or any of the subtypes. These data support the hypothesis for a role of HPgV in the aetiology of multiple lymphoma subtypes.

KW - HPgV

KW - Infection

KW - Lymphoma

KW - Prognosis

KW - Risk

UR - http://www.scopus.com/inward/record.url?scp=85047742583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047742583&partnerID=8YFLogxK

U2 - 10.1111/bjh.15416

DO - 10.1111/bjh.15416

M3 - Article

C2 - 29808922

AN - SCOPUS:85047742583

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

ER -